risedronic acid has been researched along with Hematologic Neoplasms in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tauchmanovà, L | 1 |
| Selleri, C | 1 |
| Esposito, M | 1 |
| Di Somma, C | 1 |
| Orio, F | 1 |
| Bifulco, G | 1 |
| Palomba, S | 1 |
| Lombardi, G | 1 |
| Rotoli, B | 1 |
| Colao, A | 1 |
1 trial available for risedronic acid and Hematologic Neoplasms
| Article | Year |
|---|---|
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.
Topics: Administration, Oral; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administr | 2003 |